Literature DB >> 28601573

Upregulation of cyclin B1 plays potential roles in the invasiveness of pituitary adenomas.

Peng Zhao1, Pengfei Zhang2, Wei Hu3, Hongyun Wang4, Guoqiang Yu5, Zhuang Wang4, Chuzhong Li4, Jiwei Bai2, Yazhuo Zhang4.   

Abstract

Predicting aggressive or malignant behavior of pituitary adenomas (PAs) remains challenging. Aberrant expression of cyclin B1 (CCNB1) occurred in various tumors including PAs. Our study was aimed to explore its roles in the development of PAs aggressiveness. According to the integrated analysis, the expression of CCNB1 was evaluated. Following bioinformatics analysis was performed to uncover the pathways CCNB1 involved in and the upstream transcriptional regulation factors. The mRNA expression of CCNB1 was verified by qRT-PCR. Immunohistochemistry analysis was conducted to examine the expression of CCNB1 protein in three groups of PAs (non-invasive, invasive and aggressive-invasive). In this study, CCNB1 was up-regulated in PAs versus normal pituitary. Functional annotation revealed CCNB1 was mainly involved in p53 signaling pathway and cell cycle, which affected proliferation and contributed to tumorigenesis. The constructed transcriptional regulatory network contained 22 upstream transcriptional factors for CCNB1. Moreover, the network also suggested the interactions between CCNB1 and other genes implicated in proliferation (BUB1, CDC25C and TTK). Immunohistochemistry showed staining of CCNB1 was positive in PAs, and its expression was gradually enhanced with the increased invasiveness. In conclusion, up-regulation of CCNB1, together with other regulatory molecules in cell cycle, may play roles in the PAs pathology and could be an indicator for invasiveness of PAs.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CCNB1; Cell cycle; Invasiveness; Pituitary adenomas

Mesh:

Substances:

Year:  2017        PMID: 28601573     DOI: 10.1016/j.jocn.2017.05.005

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  7 in total

1.  A systematic review of molecular alterations in invasive non-functioning pituitary adenoma.

Authors:  Nazanin Hosseinkhan; Maryam Honardoost; Zahra Emami; Sara Cheraghi; Nahid Hashemi-Madani; Mohammad E Khamseh
Journal:  Endocrine       Date:  2022-06-16       Impact factor: 3.925

2.  Comprehensive Analysis of Candidate Diagnostic and Prognostic Biomarkers Associated with Lung Adenocarcinoma.

Authors:  Jingyuan Li; Xingyuan Liu; Zan Cui; Guanying Han
Journal:  Med Sci Monit       Date:  2020-06-24

3.  Regulating the CCNB1 gene can affect cell proliferation and apoptosis in pituitary adenomas and activate epithelial-to-mesenchymal transition.

Authors:  Bin Li; Hai-Bo Zhu; Gui-Dong Song; Jian-Hua Cheng; Chu-Zhong Li; Ya-Zhuo Zhang; Peng Zhao
Journal:  Oncol Lett       Date:  2019-09-10       Impact factor: 2.967

4.  Identification and validation of three core genes in p53 signaling pathway in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Mingxue Yu; Wenli Xu; Yusheng Jie; Jiahui Pang; Siqi Huang; Jing Cao; Jiao Gong; Xinhua Li; Yutian Chong
Journal:  World J Surg Oncol       Date:  2021-03-08       Impact factor: 2.754

5.  CCNB1 affects cavernous sinus invasion in pituitary adenomas through the epithelial-mesenchymal transition.

Authors:  Bin Li; Jianhua Cheng; Hongyun Wang; Sida Zhao; Haibo Zhu; Chuzhong Li; Yazhuo Zhang; Peng Zhao
Journal:  J Transl Med       Date:  2019-10-04       Impact factor: 5.531

6.  Identification of CDC25C as a Potential Biomarker in Hepatocellular Carcinoma Using Bioinformatics Analysis.

Authors:  Ruifeng Xun; Hougen Lu; Xianwang Wang
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

7.  Molecular differences across invasive lung adenocarcinoma morphological subgroups.

Authors:  Bo Ci; Donghan M Yang; Ling Cai; Lin Yang; Luc Girard; Junya Fujimoto; Ignacio I Wistuba; Yang Xie; John D Minna; William Travis; Guanghua Xiao
Journal:  Transl Lung Cancer Res       Date:  2020-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.